Eutilex유틸렉스
263050 · KOSDAQ · ₩263050 · 유틸렉스
- Market cap
- ₩35B
- Enterprise value
- ₩50B
- P/E
- —
- P/B
- 3.4×
- Dividend yield
- 0.0%
- ROE
- −194.4%
- Net margin
- −265.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−39.6% from the high
₩650Today: ₩959 – ₩959₩1,587
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD−13.4%
- 1Y−32.6%
- Volume today
- —
- Traded today
- —
- Listed shares
- 36,834,856
- EPS (12 months)
- −₩556
- Earnings yield −57.9%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Eutilex stock overview
Eutilex (유틸렉스, KRX: 263050) is listed on KOSDAQ, in the Biotech & Pharma sector. The company was founded in 2015 and conducts research and development in cell and gene therapies, including CAR-T, and antibody therapeutics for cancer immunotherapy. Its shares closed at ₩959 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩35B.
Key facts
- Market cap
- ₩35B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- The company was founded in 2015 and conducts research and development in cell and gene therapies, including CAR-T, and antibody therapeutics for cancer immunotherapy.
Quick answers about Eutilex
- What does Eutilex do?
- The company was founded in 2015 and conducts research and development in cell and gene therapies, including CAR-T, and antibody therapeutics for cancer immunotherapy. Its lead pipeline candidates include EU307, a GPC3-targeted CAR-T therapy for solid tumors such as liver cancer, and EU103, an antibody therapy that aims to convert immunosuppressive M2 macrophages into M1 macrophages. The company also operates an IT business providing system integration, system management and IT consulting services, along with research facility and contract research services, primarily serving customers in Korea.
- What is the market cap of Eutilex?
- The market capitalisation of Eutilex was ₩35B at the close on Oct 27, 2026.
- Who are the largest shareholders of Eutilex?
- According to the latest official filings, the largest reported holders are Cheongan Investment (10.98%, as of Dec 10, 2025); Kwon Byung-se (7.03%, as of Jan 20, 2026); National Pension Service (0.74%, as of Dec 31, 2021).
- When is the next earnings report from Eutilex?
- Korean companies rarely announce results dates in advance. Based on when Eutilex filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Eutilex?
- Yes. The National Pension Service held 0.74% of Eutilex shares as of Dec 31, 2021.
Company profile
The company was founded in 2015 and conducts research and development in cell and gene therapies, including CAR-T, and antibody therapeutics for cancer immunotherapy. Its lead pipeline candidates include EU307, a GPC3-targeted CAR-T therapy for solid tumors such as liver cancer, and EU103, an antibody therapy that aims to convert immunosuppressive M2 macrophages into M1 macrophages. The company also operates an IT business providing system integration, system management and IT consulting services, along with research facility and contract research services, primarily serving customers in Korea.
Written by AI from the company's latest annual report.
- Korean name
- 유틸렉스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 권병세, 안용섭 (각자대표이사)
- Founded
- Feb 2015
- Listed
- Dec 2018
- Listed shares
- 36,834,856
- Fiscal year ends
- Month 12
- Website
- www.eutilex.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Change of CEOSep 22, 2026
- Amended: Change of CEOAug 31, 2026
- Change of CEOAug 28, 2026
- Results of Extraordinary Shareholders' MeetingAug 28, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsAug 28, 2026
Titles in Korean until English translations are added.
Also known as: Eutilex / 유틸렉스 / 263050 / KRX:263050
Source: KRX statistical information